Payment overview · 2025
General Payments
$95.10
5 reported records · 4 companies
Healthcare provider profile · identity verified
Andreh Carapiet, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · GLENDALE, CA · NPI 1649520909
Verified facts
What the public records show
CMS Open Payments records show Andreh Carapiet, M.D. received $95.10 in general payments during 2025 across 5 reported records.
Phathom Pharmaceuticals, Inc. accounted for 30.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $28.89 | 30.4% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $27.70 | 29.1% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $23.25 | 24.4% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $15.26 | 16.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $95.10 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $28.89 | 2 | 2025 |
Source payment records
|
|||||
| MITRACLIP Normalized: mitraclip |
Device | Abbott Laboratories | $27.70 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $23.25 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $15.26 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
60 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 766 | 161 |
| Amlodipine Besylate | Amlodipine Besylate | 419 | 109 |
| Levothyroxine Sodium | Levothyroxine Sodium | 358 | 74 |
| Omeprazole | Omeprazole | 335 | 71 |
| Metformin Hcl | Metformin Hcl | 317 | 66 |
| Tamsulosin Hcl | Tamsulosin Hcl | 306 | 65 |
| Losartan Potassium | Losartan Potassium | 276 | 72 |
| Gabapentin | Gabapentin | 253 | 53 |
| Lisinopril | Lisinopril | 224 | 46 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 212 | 50 |
| Metoprolol Succinate | Metoprolol Succinate | 186 | 47 |
| Pantoprazole Sodium | Pantoprazole Sodium | 178 | 48 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 153 | 41 |
| Alendronate Sodium | Alendronate Sodium | 148 | 23 |
| Donepezil Hcl | Donepezil Hcl | 146 | 28 |
| Clopidogrel | Clopidogrel Bisulfate | 145 | 29 |
| Vascepa | Icosapent Ethyl | 143 | 20 |
| Famotidine | Famotidine | 136 | 37 |
| Finasteride | Finasteride | 136 | 26 |
| Furosemide | Furosemide | 126 | 35 |
| Eliquis | Apixaban | 118 | 31 |
| Tramadol Hcl | Tramadol Hcl | 111 | 32 |
| Carvedilol | Carvedilol | 99 | 21 |
| Ibuprofen | Ibuprofen | 97 | 26 |
| Fluticasone Propionate | Fluticasone Propionate | 96 | 24 |
| Icosapent Ethyl | Icosapent Ethyl | 96 | 19 |
| Simvastatin | Simvastatin | 94 | 16 |
| Metoprolol Tartrate | Metoprolol Tartrate | 93 | 23 |
| Quetiapine Fumarate | Quetiapine Fumarate | 93 | 21 |
| Jardiance | Empagliflozin | 89 | 17 |
| Januvia | Sitagliptin Phosphate | 85 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 85 | 20 |
| Trazodone Hcl | Trazodone Hcl | 85 | 18 |
| Hydrochlorothiazide | Hydrochlorothiazide | 83 | 20 |
| Escitalopram Oxalate | Escitalopram Oxalate | 74 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 74 | 19 |
| Meclizine Hcl | Meclizine Hcl | 72 | 13 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 70 | 12 |
| Montelukast Sodium | Montelukast Sodium | 70 | 13 |
| Glipizide | Glipizide | 68 | 16 |
| Linzess | Linaclotide | 66 | 15 |
| Meloxicam | Meloxicam | 65 | 12 |
| Memantine Hcl | Memantine Hcl | 65 | 15 |
| Atenolol | Atenolol | 64 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 61 | suppressed |
| Levetiracetam | Levetiracetam | 61 | 15 |
| Ozempic | Semaglutide | 60 | 15 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 59 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 57 | 20 |
| Mirtazapine | Mirtazapine | 56 | 15 |
| Fenofibrate | Fenofibrate,micronized | 55 | suppressed |
| Myrbetriq | Mirabegron | 55 | suppressed |
| Ezetimibe | Ezetimibe | 52 | 17 |
| Xarelto | Rivaroxaban | 52 | 13 |
| Glimepiride | Glimepiride | 51 | suppressed |
| Azithromycin | Azithromycin | 49 | 38 |
| Repatha Sureclick | Evolocumab | 49 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 48 | suppressed |
| Fenofibrate | Fenofibrate | 48 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 48 | 16 |
| Spironolactone | Spironolactone | 46 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 45 | suppressed |
| Valsartan | Valsartan | 45 | suppressed |
| Potassium Chloride | Potassium Chloride | 44 | 14 |
| Levemir Flexpen | Insulin Detemir | 43 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 42 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 40 | suppressed |
| Nifedipine Er | Nifedipine | 40 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 39 | 13 |
| Humalog Kwikpen U-100 | Insulin Lispro | 38 | suppressed |
| Hydrocortisone | Hydrocortisone | 38 | suppressed |
| Tradjenta | Linagliptin | 38 | suppressed |
| Bupropion Xl | Bupropion Hcl | 37 | suppressed |
| Cyclosporine | Cyclosporine | 36 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 36 | suppressed |
| Lorazepam | Lorazepam | 35 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 34 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 34 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 33 | suppressed |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 33 | suppressed |
| Alprazolam | Alprazolam | 32 | suppressed |
| Trulicity | Dulaglutide | 32 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 29 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 29 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 29 | suppressed |
| Ondansetron Odt | Ondansetron | 29 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 28 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 28 | suppressed |
| Allopurinol | Allopurinol | 27 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 27 | 27 |
| Colchicine | Colchicine | 27 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 27 | 12 |
| Dutasteride | Dutasteride | 27 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 27 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 27 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 26 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 26 | suppressed |
| Mounjaro | Tirzepatide | 26 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 24 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 24 | suppressed |
| Latanoprost | Latanoprost | 24 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 23 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | 11 |
| Prednisone | Prednisone | 23 | 21 |
| Temazepam | Temazepam | 23 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 23 | 14 |
| Aripiprazole | Aripiprazole | 22 | suppressed |
| Brilinta | Ticagrelor | 22 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 22 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Amoxicillin | Amoxicillin | 21 | 16 |
| Bupropion Hcl Sr | Bupropion Hcl | 21 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 20 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 20 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 20 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 20 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 20 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 19 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 19 | suppressed |
| Clonazepam | Clonazepam | 19 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 19 | suppressed |
| Baclofen | Baclofen | 18 | suppressed |
| Bumetanide | Bumetanide | 18 | suppressed |
| Chlorthalidone | Chlorthalidone | 18 | suppressed |
| Ketoconazole | Ketoconazole | 18 | suppressed |
| Lovastatin | Lovastatin | 18 | suppressed |
| Methylprednisolone | Methylprednisolone | 18 | 15 |
| Cilostazol | Cilostazol | 17 | suppressed |
| Diazepam | Diazepam | 17 | suppressed |
| Lidocaine | Lidocaine | 17 | suppressed |
| Mupirocin | Mupirocin | 17 | suppressed |
| Olanzapine | Olanzapine | 17 | suppressed |
| Restasis | Cyclosporine | 17 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 17 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 17 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 16 | suppressed |
| Novolog Flexpen | Insulin Aspart | 16 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 16 | suppressed |
| Nitroglycerin | Nitroglycerin | 15 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Celecoxib | Celecoxib | 14 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 14 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 14 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 13 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 13 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 13 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | 12 |
| Creon | Lipase/Protease/Amylase | 13 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 13 | suppressed |
| Hydrocortisone Butyrate | Hydrocortisone Butyrate | 13 | suppressed |
| Lactulose | Lactulose | 13 | suppressed |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 13 | suppressed |
| Methimazole | Methimazole | 13 | suppressed |
| Multaq | Dronedarone Hcl | 13 | suppressed |
| Sulindac | Sulindac | 13 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 12 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Cialis | Tadalafil | 11 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 11 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 11 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 11 | suppressed |
| Mesalamine | Mesalamine | 11 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 11 | suppressed |
| Misoprostol | Misoprostol | 11 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 11 | suppressed |
| Sure Comfort Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Ursodiol | Ursodiol | 11 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $95.10 · 5 records | Phathom Pharmaceuticals, Inc. | Dexcom G6 Transmitter, MITRACLIP, VOQUEZNA, Wegovy | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error